-+ 0.00%
-+ 0.00%
-+ 0.00%

REVOLUTION MEDICINES ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 CLINICAL TRIAL EVALUATING DARAXONRASIB IN PREVIOUSLY TREATED PATIENTS WITH RAS MUTANT NON-SMALL CELL LUNG CANCER

Reuters·05/14/2025 12:00:03

Please log in to view news